Rachael Torres Whitney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rachael Torres Whitney has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Adam Davey
Department of Behavioral Health and Nutrition, College of Health Sciences, University of Delaware, Newark, DE, USA
7 shared publicationsMerrill F. Elias
Department of Psychology, University of Maine, Orono, ME, USA
6 shared publicationsMerrill F Elias
Department of Psychology and Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, USA
3 shared publications- Merrill F. Elias
Department of Psychology, The University of Maine, Orono, ME, USA
3 shared publications - Georgina E. Crichton
Alliance for Research in Exercise, Nutrition and Activity (ARENA), Sansom Institute for Health Research, University of South Australia, Adelaide 5001, Australia
2 shared publications Michael A. Robbins
Department of Psychology and Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, USA
2 shared publications
Latest Publications
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (2)
Association of Pre-stroke Cardiovascular Risk With Post-stroke Cognitive Decline and Dementia
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (2)
Association of Pre-stroke Cardiovascular Risk With Post-stroke Cognitive Decline and Dementia
- 8 December 2018
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 32 (3) , 237-239
Carotid Artery Blood Flow Velocities and Cognitive Performance: Forecasting Cognitive Decline
- 8 December 2018
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 32 (3) , 237-239
Carotid Artery Blood Flow Velocities and Cognitive Performance: Forecasting Cognitive Decline
- 3 August 2018
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 31 (12) , 1263-1265
Diastolic Blood Pressure, Not Just Systolic Blood Pressure, Is Related to Cerebral Measures in Middle Age: Implications for Prospective Studies
The two fundamental components of blood pressure (BP) are systolic BP (SBP) and diastolic BP (DBP). Debate over the prognostic importance of each component at middle age represents an important period in the history of hypertension, as it relates to the prediction of cardiovascular outcomes and brain injury. In recounting this history, Schillaci et al.1 point out that the emphasis on SBP was supported by literature indicating that it is a stronger predictor of cardiovascular morbidity and mortality than DBP in mature adults and elderly persons. They describe the emphasis on SBP that followed in the literature and how it led to a rather extreme movement to discard DBP as prognostically important in...
- 3 August 2018
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 31 (12) , 1263-1265
Diastolic Blood Pressure, Not Just Systolic Blood Pressure, Is Related to Cerebral Measures in Middle Age: Implications for Prospective Studies
The two fundamental components of blood pressure (BP) are systolic BP (SBP) and diastolic BP (DBP). Debate over the prognostic importance of each component at middle age represents an important period in the history of hypertension, as it relates to the prediction of cardiovascular outcomes and brain injury. In recounting this history, Schillaci et al.1 point out that the emphasis on SBP was supported by literature indicating that it is a stronger predictor of cardiovascular morbidity and mortality than DBP in mature adults and elderly persons. They describe the emphasis on SBP that followed in the literature and how it led to a rather extreme movement to discard DBP as prognostically important in...
- Open Access
- 22 February 2018
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 31 (6) , 631-642
Clinical Trials of Blood Pressure Lowering and Antihypertensive Medication: Is Cognitive Measurement State-of-the-Art?
Randomized controlled trials of blood pressure (BP) lowering and antihypertensive medication use on cognitive outcomes have often been disappointing, reporting mixed findings and small effect sizes. We evaluate the extent to which cognitive assessment protocols used in these trials approach state-of-the-art. Overall, we find that a primary focus on cognition and the systematic selection of cognitive outcomes across trials take a backseat to other trial goals. Twelve trials investigating change in cognitive functioning were examined and none met criteria for state-of-the-art assessment, including use of at least 4 tests indexing 2 cognitive domains. Four trials investigating incident dementia were also examined. Each trial used state-of-the-art diagnostic criteria to assess dementia, although follow-up periods were relatively short, with only 2 trials lasting for at least 3 years. Weaknesses in each trial may act to obscure or weaken the positive effects of BP lowering on cognitive functioning. Improving trial designs in terms of cognitive outcomes selected and length of follow-up periods employed could lead to more promising findings. We offer logical steps to achieve state-of-the-art assessment protocols, with examples, in hopes of improving future trials.
- 22 February 2018
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 31 (6) , 631-642
Open AccessClinical Trials of Blood Pressure Lowering and Antihypertensive Medication: Is Cognitive Measurement State-of-the-Art?
Randomized controlled trials of blood pressure (BP) lowering and antihypertensive medication use on cognitive outcomes have often been disappointing, reporting mixed findings and small effect sizes. We evaluate the extent to which cognitive assessment protocols used in these trials approach state-of-the-art. Overall, we find that a primary focus on cognition and the systematic selection of cognitive outcomes across trials take a backseat to other trial goals. Twelve trials investigating change in cognitive functioning were examined and none met criteria for state-of-the-art assessment, including use of at least 4 tests indexing 2 cognitive domains. Four trials investigating incident dementia were also examined. Each trial used state-of-the-art diagnostic criteria to assess dementia, although follow-up periods were relatively short, with only 2 trials lasting for at least 3 years. Weaknesses in each trial may act to obscure or weaken the positive effects of BP lowering on cognitive functioning. Improving trial designs in terms of cognitive outcomes selected and length of follow-up periods employed could lead to more promising findings. We offer logical steps to achieve state-of-the-art assessment protocols, with examples, in hopes of improving future trials.
- Open Access
- 19 September 2017
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 19 (12) , 1357-1365
Systolic orthostatic hypotension is related to lowered cognitive function: Findings from the Maine‐Syracuse Longitudinal Study
The aim of the present study was to examine the relationship between orthostatic changes in blood pressure (BP) and cognition, with consideration given to cardiovascular risk factors and lifestyle variables. The cross‐sectional analysis included 961 community‐dwelling participants of the Maine‐Syracuse Longitudinal Study, for whom BP clinic measures (five sitting, five recumbent, and five standing) were obtained. Eighteen percent of participants had orthostatic hypotension (fall in systolic BP ≥20 mm Hg or diastolic BP ≥10 mm Hg upon standing) and 6% had orthostatic hypertension (rise in systolic BP ≥20 mm Hg). Orthostatic hypotension and hypertension defined using traditional criteria were unrelated to cognition with covariate adjustment. However, an examination of systolic and diastolic BP change independently revealed that participants with systolic orthostatic hypotension had poorer global cognition, verbal memory, and scanning and tracking scores than those with normal systolic BP change. The authors conclude that systolic orthostatic hypotension is significantly associated with reduced cognitive function.
- 19 September 2017
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 19 (12) , 1357-1365
Open AccessSystolic orthostatic hypotension is related to lowered cognitive function: Findings from the Maine‐Syracuse Longitudinal Study
The aim of the present study was to examine the relationship between orthostatic changes in blood pressure (BP) and cognition, with consideration given to cardiovascular risk factors and lifestyle variables. The cross‐sectional analysis included 961 community‐dwelling participants of the Maine‐Syracuse Longitudinal Study, for whom BP clinic measures (five sitting, five recumbent, and five standing) were obtained. Eighteen percent of participants had orthostatic hypotension (fall in systolic BP ≥20 mm Hg or diastolic BP ≥10 mm Hg upon standing) and 6% had orthostatic hypertension (rise in systolic BP ≥20 mm Hg). Orthostatic hypotension and hypertension defined using traditional criteria were unrelated to cognition with covariate adjustment. However, an examination of systolic and diastolic BP change independently revealed that participants with systolic orthostatic hypotension had poorer global cognition, verbal memory, and scanning and tracking scores than those with normal systolic BP change. The authors conclude that systolic orthostatic hypotension is significantly associated with reduced cognitive function.
- 1 July 2017
- Published by Wolters Kluwer Health in Hypertension
- Vol. 70 (1) , 30-31
Delayed Response to Antihypertension Medication
- 1 July 2017
- Published by Wolters Kluwer Health in Hypertension
- Vol. 70 (1) , 30-31
Delayed Response to Antihypertension Medication
- Open Access
- 11 April 2017
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 30 (6) , 556-558
Intensive Blood Pressure Control Improves Cognitive Performance: Pushing the Envelope cum Judicia
Hypertension is related to lower levels of cognitive performance and increased risk for mild cognitive impairment and dementia.1 Cut points for hypertension have been revised downward over time, with current diagnostic criteria of ≥140/90 mm Hg for hypertension and 120/80 to 139/89 mm Hg for prehypertension.1–3 This trend is consistent with well-established findings that: (i) blood pressure (BP) is inversely associated with cognitive performance across the full range of normal and hypertensive BP levels1–3 and; (ii) clinically notable reductions in cardiovascular events and death are observed following BP control to traditional (2–6
- 11 April 2017
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 30 (6) , 556-558
Open AccessIntensive Blood Pressure Control Improves Cognitive Performance: Pushing the Envelope cum Judicia
Hypertension is related to lower levels of cognitive performance and increased risk for mild cognitive impairment and dementia.1 Cut points for hypertension have been revised downward over time, with current diagnostic criteria of ≥140/90 mm Hg for hypertension and 120/80 to 139/89 mm Hg for prehypertension.1–3 This trend is consistent with well-established findings that: (i) blood pressure (BP) is inversely associated with cognitive performance across the full range of normal and hypertensive BP levels1–3 and; (ii) clinically notable reductions in cardiovascular events and death are observed following BP control to traditional (2–6
- 1 February 2017
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 69 (2) , 163-165
Albuminuria and Cognitive Performance: New Evidence for Consideration of a Risk Factor Precursor Model From the Maastricht Study
- 1 February 2017
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 69 (2) , 163-165
Albuminuria and Cognitive Performance: New Evidence for Consideration of a Risk Factor Precursor Model From the Maastricht Study
- Open Access
- 8 March 2016
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 32 (2) , 299-306
Risk for cognitive impairment across 22 measures of cognitive ability in early-stage chronic kidney disease
Background: Chronic kidney disease (CKD) is a significant risk factor for cognitive impairment. Previous studies have examined differences in cognitive impairment between persons with and without CKD using multiple cognitive outcomes, but few have done this for an extensive battery of cognitive tests. We relate early-stage CKD to two indices of impairment for 22 measures of cognitive ability. Methods: The study was community-based and cross-sectional with 898 individuals free from dementia and end-stage renal disease. Estimated glomerular filtration rate (eGFR) was calculated using the chronic kidney disease epidemiology collaboration equation and classified as 2, based on consensus definitions of Stage 3 or greater CKD. The eGFR classifications were related to modest [≥1 standard deviation (SD) below the mean] and severe (≥1.5 SD below the mean) impairment on each measure using logistic regression analyses adjusting for potential risk factors. Results: A total of 146 individuals (16.3%) had eGFR 2 (mean 51.6 ± 10.1 mL/min/1.73 m2). These participants had significantly greater risk for modestly impaired abilities in the scanning and tracking and visual-spatial organization/memory (VSOM) domains after accounting for comorbidity-related risk factors [odds ratios (ORs) between 1.68 and 2.16], as well as greater risk for severely impaired functioning in the language domain (OR = 2.65). Conclusions: Participants with eGFR 2 were at higher risk for cognitive impairment than those with eGFR ≥60 mL/min/1.73 m2 on the majority of cognitive abilities, specifically those within the VSOM, Language, and scanning and tracking domains. Targeted screening for cognitive deficits in kidney disease patients early in their disease course may be warranted.
- 8 March 2016
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 32 (2) , 299-306
Open AccessRisk for cognitive impairment across 22 measures of cognitive ability in early-stage chronic kidney disease
Background: Chronic kidney disease (CKD) is a significant risk factor for cognitive impairment. Previous studies have examined differences in cognitive impairment between persons with and without CKD using multiple cognitive outcomes, but few have done this for an extensive battery of cognitive tests. We relate early-stage CKD to two indices of impairment for 22 measures of cognitive ability. Methods: The study was community-based and cross-sectional with 898 individuals free from dementia and end-stage renal disease. Estimated glomerular filtration rate (eGFR) was calculated using the chronic kidney disease epidemiology collaboration equation and classified as 2, based on consensus definitions of Stage 3 or greater CKD. The eGFR classifications were related to modest [≥1 standard deviation (SD) below the mean] and severe (≥1.5 SD below the mean) impairment on each measure using logistic regression analyses adjusting for potential risk factors. Results: A total of 146 individuals (16.3%) had eGFR 2 (mean 51.6 ± 10.1 mL/min/1.73 m2). These participants had significantly greater risk for modestly impaired abilities in the scanning and tracking and visual-spatial organization/memory (VSOM) domains after accounting for comorbidity-related risk factors [odds ratios (ORs) between 1.68 and 2.16], as well as greater risk for severely impaired functioning in the language domain (OR = 2.65). Conclusions: Participants with eGFR 2 were at higher risk for cognitive impairment than those with eGFR ≥60 mL/min/1.73 m2 on the majority of cognitive abilities, specifically those within the VSOM, Language, and scanning and tracking domains. Targeted screening for cognitive deficits in kidney disease patients early in their disease course may be warranted.
- 4 March 2016
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 115 (8) , 1397-1405
Sugar-sweetened soft drinks are associated with poorer cognitive function in individuals with type 2 diabetes: the Maine–Syracuse Longitudinal Study
The importance of adequate nutrition on cognitive performance is well recognised. Greater intakes of soft drinks are associated with a higher risk for type 2 diabetes, as well as other cardiometabolic diseases. A few studies have specifically examined whether the intake of soft drinks may be related to cognitive function. The aim of this study was to investigate whether soft drink intakes, including both sugar-sweetened and diet beverages, are associated with cognitive function, with adjustment for cardiovascular, lifestyle and dietary factors, and stratified according to type 2 diabetes status. Cross-sectional analyses were undertaken using 803 community-dwelling participants, aged 23–98 years, from the Maine–Syracuse Longitudinal Study. Cognitive function was measured using an extensive battery of neuropsychological tests. Usual dietary intake of soft drinks was assessed using a FFQ. Stratification by type 2 diabetes indicated that a greater intake of sugar-sweetened soft drinks was significantly associated with poorer performance in visual spatial memory, working memory, scanning and tracking, executive function, the global composite and the Mini-Mental State Examination in diabetic individuals. These relations were not attenuated with statistical control for BMI and other cardiovascular, lifestyle and dietary factors. Diet soft drink intake was unrelated to cognitive performance. Frequent sugar-sweetened soft drink intake was associated with poorer cognitive performance, particularly in individuals with type 2 diabetes, but the underlying causal mechanisms are yet to be determined. Longitudinal studies are needed to clarify these findings and the underlying causal mechanisms.
- 4 March 2016
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 115 (8) , 1397-1405
Sugar-sweetened soft drinks are associated with poorer cognitive function in individuals with type 2 diabetes: the Maine–Syracuse Longitudinal Study
The importance of adequate nutrition on cognitive performance is well recognised. Greater intakes of soft drinks are associated with a higher risk for type 2 diabetes, as well as other cardiometabolic diseases. A few studies have specifically examined whether the intake of soft drinks may be related to cognitive function. The aim of this study was to investigate whether soft drink intakes, including both sugar-sweetened and diet beverages, are associated with cognitive function, with adjustment for cardiovascular, lifestyle and dietary factors, and stratified according to type 2 diabetes status. Cross-sectional analyses were undertaken using 803 community-dwelling participants, aged 23–98 years, from the Maine–Syracuse Longitudinal Study. Cognitive function was measured using an extensive battery of neuropsychological tests. Usual dietary intake of soft drinks was assessed using a FFQ. Stratification by type 2 diabetes indicated that a greater intake of sugar-sweetened soft drinks was significantly associated with poorer performance in visual spatial memory, working memory, scanning and tracking, executive function, the global composite and the Mini-Mental State Examination in diabetic individuals. These relations were not attenuated with statistical control for BMI and other cardiovascular, lifestyle and dietary factors. Diet soft drink intake was unrelated to cognitive performance. Frequent sugar-sweetened soft drink intake was associated with poorer cognitive performance, particularly in individuals with type 2 diabetes, but the underlying causal mechanisms are yet to be determined. Longitudinal studies are needed to clarify these findings and the underlying causal mechanisms.